These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 37623925)

  • 1. Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy.
    Newell S; van der Watt PJ; Leaner VD
    IUBMB Life; 2024 Jan; 76(1):4-25. PubMed ID: 37623925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The nuclear export protein exportin-1 in solid malignant tumours: From biology to clinical trials.
    Lai C; Xu L; Dai S
    Clin Transl Med; 2024 May; 14(5):e1684. PubMed ID: 38783482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nucleo-cytoplasmic transport as a therapeutic target of cancer.
    Gravina GL; Senapedis W; McCauley D; Baloglu E; Shacham S; Festuccia C
    J Hematol Oncol; 2014 Dec; 7():85. PubMed ID: 25476752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein.
    Ishizawa J; Kojima K; Hail N; Tabe Y; Andreeff M
    Pharmacol Ther; 2015 Sep; 153():25-35. PubMed ID: 26048327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Importins and exportins as therapeutic targets in cancer.
    Mahipal A; Malafa M
    Pharmacol Ther; 2016 Aug; 164():135-43. PubMed ID: 27113410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting nuclear transporters in cancer: Diagnostic, prognostic and therapeutic potential.
    Stelma T; Chi A; van der Watt PJ; Verrico A; Lavia P; Leaner VD
    IUBMB Life; 2016 Apr; 68(4):268-80. PubMed ID: 26970212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents.
    Turner JG; Dawson J; Cubitt CL; Baz R; Sullivan DM
    Semin Cancer Biol; 2014 Aug; 27():62-73. PubMed ID: 24631834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear export mediated regulation of microRNAs: potential target for drug intervention.
    Muqbil I; Bao B; Abou-Samra AB; Mohammad RM; Azmi AS
    Curr Drug Targets; 2013 Sep; 14(10):1094-100. PubMed ID: 23834155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting XPO1-Dependent Nuclear Export in Cancer.
    Kim E; Mordovkina DA; Sorokin A
    Biochemistry (Mosc); 2022 Jan; 87(Suppl 1):S178-S70. PubMed ID: 35501995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective Inhibitors of Nuclear Export in the Treatment of Hematologic Malignancies.
    Allegra A; Innao V; Allegra AG; Leanza R; Musolino C
    Clin Lymphoma Myeloma Leuk; 2019 Nov; 19(11):689-698. PubMed ID: 31543372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nuclear export protein XPO1 - from biology to targeted therapy.
    Azmi AS; Uddin MH; Mohammad RM
    Nat Rev Clin Oncol; 2021 Mar; 18(3):152-169. PubMed ID: 33173198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia.
    Lapalombella R; Sun Q; Williams K; Tangeman L; Jha S; Zhong Y; Goettl V; Mahoney E; Berglund C; Gupta S; Farmer A; Mani R; Johnson AJ; Lucas D; Mo X; Daelemans D; Sandanayaka V; Shechter S; McCauley D; Shacham S; Kauffman M; Chook YM; Byrd JC
    Blood; 2012 Nov; 120(23):4621-34. PubMed ID: 23034282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting of nucleo‑cytoplasmic transport factor exportin 1 in malignancy (Review).
    Özdaş S; Canatar İ
    Med Int (Lond); 2022; 2(1):2. PubMed ID: 38938904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRM1-mediated nuclear export of proteins and drug resistance in cancer.
    Turner JG; Sullivan DM
    Curr Med Chem; 2008; 15(26):2648-55. PubMed ID: 18991627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.
    Walker CJ; Oaks JJ; Santhanam R; Neviani P; Harb JG; Ferenchak G; Ellis JJ; Landesman Y; Eisfeld AK; Gabrail NY; Smith CL; Caligiuri MA; Hokland P; Roy DC; Reid A; Milojkovic D; Goldman JM; Apperley J; Garzon R; Marcucci G; Shacham S; Kauffman MG; Perrotti D
    Blood; 2013 Oct; 122(17):3034-44. PubMed ID: 23970380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The hippo kinase STK38 ensures functionality of XPO1.
    Martin AP; Camonis JH
    Cell Cycle; 2020 Nov; 19(22):2982-2995. PubMed ID: 33017560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding XPO1 target networks using systems biology and mathematical modeling.
    Muqbil I; Kauffman M; Shacham S; Mohammad RM; Azmi AS
    Curr Pharm Des; 2014; 20(1):56-65. PubMed ID: 23530499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export.
    Neggers JE; Vanstreels E; Baloglu E; Shacham S; Landesman Y; Daelemans D
    Oncotarget; 2016 Oct; 7(42):68842-68850. PubMed ID: 27634897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nucleocytoplasmic Shuttling of Porcine Parvovirus NS1 Protein Mediated by the CRM1 Nuclear Export Pathway and the Importin α/β Nuclear Import Pathway.
    Cao L; Fu F; Chen J; Shi H; Zhang X; Liu J; Shi D; Huang Y; Tong D; Feng L
    J Virol; 2022 Jan; 96(1):e0148121. PubMed ID: 34643426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective inhibitors of nuclear export (SINE)--a novel class of anti-cancer agents.
    Parikh K; Cang S; Sekhri A; Liu D
    J Hematol Oncol; 2014 Oct; 7():78. PubMed ID: 25316614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.